

Appendix 3 (as supplied by the authors): Excluded documents list

Review One: Breast Cancer Risk, Prognosis and Mortality in the Trans Population using Cross-sex Hormones: A Systematic Review

Documents excluded at full-text screening (n = 59)

Reason for exclusion: Population out of scope (n = 8)

1. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003;362(9390):1160.
2. Dimitrov, NV, Colucci P, Nagpal, S. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer. *Oncologist*. 2007;12:798-807.
3. El-Beshbeshi W, Abo-Elnaga EM. Male breast cancer: 10-year experience at Mansoura University Hospital in Egypt. *Cancer Biol Med*. 2012;9:23-8.
4. Glaser RL, Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. *Maturitas*. 2013;76(4):342-9.
5. O'Brien B, Koru-Sengul T, Saclarides C, Franceschi D, Lee DJ, Miao F, Tannenbaum S, Bryne MM, Avisar E. Disparities in male breast cancer - the Florida experience. *Ann Surg Oncol*. 2014;21:88-9.
6. Talpur KAH, Laghari AA, Malik AM, Memon A. Clinico-pathological profile of patients with breast diseases at university hospital, Jamshoro. *J Liaquat Uni Med Health Sci*. 2006;5(2):71-75.
7. Yu E, Stitt L, Vujovic O, Joseph K, Assouline A, Au J, Younus J, Perera F, Tai P. Prognostic factors for male breast cancer: similarity to female counterparts. *Anticancer Res*. 2013;33(5):2227-31.
8. Yu E, Stitt L, Vujovic O, Joseph K, Assouline A, Au J, Younus J, Perera F, Tai P. Male breast cancer prognostic factors: similarity to female counterparts with propensity scores and matched-pair analysis. *Int J Radiat Oncol Biol Phys*. 2014;90(1):S221.

Reason for exclusion: Intervention out of scope (n = 2)

9. Scheim A, Bauer G, for the TransPULSE Team. Breast and cervical cancer screening among trans Ontarians: a report prepared for the Screening Saves Lives Program of the Canadian Cancer Society [Internet]. Ontario, Canada: TransPULSE Project; 2013 [cited 2017 May 9]. Available at:

http://transpulseproject.ca/wp-content/uploads/2013/11/Trans-PULSE-Cancer-Screening-Report-for-Screening-Saves-Lives-V_Final.pdf.

10. Weyers S, Villeirs G, Vanherreweghe E, Verstraelen H, Monstrey S, Van den Broecke R, Gerris J. Mammography and breast sonography in transsexual women. *Eur J Radiol*. 2010;74(3):508-13.

Reason for exclusion: Comparison out of scope or study without a comparison group (n = 11)

11. Dittrich R, Binder H, Cupisti S, Hoffmann I, Beckmann MW, Mueller A. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. *Exp Clin Endocrinol Diabetes*. 2005;113(10):586-92.
12. East EG, Gast K, Kuzon W, Jorns JM. Clinicopathologic findings in female to male gender reassignment surgery. *Lab Invest*. 2017;97:40A.
13. Grynberg M, Fanchin R, Dubost G, Colau JC, Bremont-Weil C, Frydman R, Ayoubi JM. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. *Reprod Biomed Online*. 2010. 20(4):553-8.
14. Hohl CA, Camara VL, Zanardi UV, Inacio M, Verduguez EU, Sircili MHP, Domenice S, Mendonca BB, Costa EMF. Efficiency and safety of low doses of estrogens associated with antiandrogens in hormonal treatment of male-to-female transsexual patients. *Endocrine Reviews*. Conference: 93rd Annual Meeting and Expo of the Endocrine Society, ENDO. 2011;32(3):Suppl. June 2011.
15. Jacobeit JW, Gooren LJ, Schulte HM. Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. *J Sex Med*. 2007;4(5):1479-84.
16. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. *Eur J Endocrinol*. 2009;161(5):795-8.
17. Meriggiola MC, Armillotta F, Costantino A, Altieri P, Saad F, Kalhorn T, Perrone AM, Ghi T, Pelusi C, Pelusi G. Effects of testosterone undecanoate administered alone or in combination with letrozole or dutasteride in female to male transsexuals. *J Sex Med*. 2008;5(1):2442-53.
18. Mueller A, Kiesewetter F, Binder H, Beckmann MW, Dittrich R. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. *J Clin Endocrinol Metab*. 2007;92(9):3470-5.
19. Schlatterer K, Yassouridis A, von Werder K, Poland D, Kemper J, Stalla GK. A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. *Arch Sex Behav*. 1998;27(5):475-92.

20. Slagter MH, Gooren LJ, Scorilas A, Petraki CD, Diamandis EP. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. *J Histochem Cytochem.* 2006;54(8):905-10.
21. Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, T'Sjoen G. Long-term evaluation of cross-sex hormone treatment in transsexual persons. *J Sex Med.* 2012;9(10):2641-51.

Reason for exclusion: Outcomes of interest not reported (n = 10)

22. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinol.* 2011;164(4):635-42.
23. Bentz EK, Pils D, Bilban M, Kaufmann U, Hefler LA, Reinthaller A, Singer CF, Huber JC, Horvat R, Tempfer CB. Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals. *Fertil Steril.* 2010;94(7):2688-96.
24. Deutsch MB, Bhakri V, Kubicek K. Effects of cross-sex hormone treatment on transgender women and men. *Obstet Gynecol.* 2015;125(3):605-10.
25. Dhejne C, Lichtenstein P, Boman M, Johansson AL, Langstrom N, Landen M. Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. *PLoS ONE.* 2011;6(2):e16885.
26. Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclair C, Barrett J. Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. *J Clin Endocrinol Metab.* 2012;97(12):4422-8.
27. Smith YL, Van Goozen SH, Kuiper AJ, Cohen-Kettenis PT. Sex reassignment: outcomes and predictors of treatment for adolescent and adult transsexuals. *Psychol Med.* 2005;35(1):89-99.
28. Tempfer C, Pils D, Bentz EK, Kaufmann U, Hefler L. Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals. *Arch Gynecol Obstet.* 2010;282(Suppl 1):S19.
29. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol (Oxf).* 1997;47(3):337-42.
30. Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, Kaufman JM, T'Sjoen G. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. *Eur J Endocrinol.* 2013;169(4):471-8.
31. Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher AD, Fisher A, Toye K, Kaufman JM, T'Sjoen G. Cross-sex hormone therapy in trans persons is safe

and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. *J Sex Med.* 2014;11(8):1999-2011.

Reason for exclusion: Study design out of scope (n = 9)

32. Brown GR. Breast cancer in transgender veterans: a ten-case series. *LGBT Health.* 2015;2(1):77-80.
33. Kanhai RC, Hage JJ, Bloemena E, van Diest PJ, Karim RB. Mammary fibroadenoma in a male-to-female transsexual. *Histopathology.* 1999;35(2):183-5.
34. Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW. Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men. *Am J Surg Pathol.* 2000;24(1):74-80.
35. Lemmo G, Garcea N, Corsello S, Tarquini E, Palladino T, Ardito G, Garcea R. Breast fibroadenoma in a male-to-female transsexual patient after hormonal treatment. *Eur J Surg Suppl.* 2003;588:69-71.
36. Maglione KD, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, Sonnenblick EB. Breast cancer in male-to-female transsexuals: use of breast imaging for detection. *AJR. Am J Roentgenol.* 2014;203(6):W735-40.
37. Sattari M. Breast cancer in male-to-female transgender patients: a case for caution. *Clin Breast Cancer.* 2015;15(1):e67-9.
38. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. *J Clin Endocrinol Metab.* 2003;88(8):3467-73
39. Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. *Lancet Diabetes Endocrinol.* 2017;5(4):291-300.
40. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. *J Sex Med.* 2010;7(11):3758-64.

Reason for exclusion: Publication type out of scope (n = 19)

41. Braunstein GD. Safety of testosterone treatment in postmenopausal women. *Fertil Steril.* 2007;88(1):1-17.
42. Chuffa LG, Lupi-Junior LA, Costa AB, Amorim JP, Seiva FR. The role of sex hormones and steroid receptors on female reproductive cancers. *Steroids.* 2017;118:93-108.
43. Feldman J, Brown GR, Deutsch MB, Hembree W, Meyer W, Meyer-Bahlburg HFL, Tangpricha V, T'Sjoen G, Safer JD. Priorities for transgender medical and healthcare research. *Curr Opin Endocrinol Diabetes Obes.* 2016;23(2):180-7.

44. Futterweit W. Endocrine therapy of transsexualism and potential complications of long-term treatment. *Arch Sex Behav.* 1998;27(2):209-26.
45. Gooren LJ. Management of female-to-male transgender persons: medical and surgical management, life expectancy. *Curr Opin Endocrinol Diabetes Obes.* 2014;21(3):233-8.
46. Gooren LJ. Hormonal sex reassignment. *Int J Transgend.* 1999;3.
47. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. *J Sex Med.* 2008;5(4):765-76.
48. Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. *J Clin Endocrinol Metab.* 2008;93(1):19-25.
49. Gooren L, Lips P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. *J Sex Med.* 2014;11(8):2012-9.
50. Irwig MS. Testosterone therapy for transgender men. *Lancet Diabetes Endocrinol.* 2017;5(4):301-311.
51. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. *Clin Endocrinol.* 2003;59(4):409-18.
52. Meriggiola MC, Berra M. Long-term cross-sex hormone treatment is safe in transsexual subjects. *Asian J Androl.* 2012;14(6):813-4.
53. Meriggiola MC, Gava G. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. *Clin Endocrinol (Oxf).* 2015;83(5):597-606.
54. Meriggiola MC, Gava G. Endocrine care of transpeople part II. A review of cross-sex hormonal treatments, outcomes and adverse effects in transwomen. *Clin Endocrinol (Oxf).* 2015;83(5):607-15.
55. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinol.* 2008;159(3):197-202.
56. Phillips N, Sharma A, Horne J. Male to female trans-gender menopause. *J Womens Health.* 2014;23(4):15-16.
57. Shufelt CL, Braunstein GD. Testosterone and the breast. *Menopause Int.* 2008;14(3):117-22.
58. Smith KP, Madison CM, Milne NM. Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults. *Pharmacotherapy.* 2014;34(12):1282-97.

59. Traish AM, Fetten K, Miner M, Hansen ML, Guay A. Testosterone and risk of breast cancer: appraisal of existing evidence. *Horm Mol Biol Clin Investig*. 2010;2(1):177-90.

Review Two: Benefits and Harms of Breast Screening for the Trans Population: A Systematic Review

Documents excluded at full-text screening (n = 48)

Reason for exclusion: Population out of scope (n = 5)

1. McElroy JA, Wintemberg JJ, Williams A. Comparison of lesbian and bisexual women to heterosexual women's screening prevalence for breast, cervical, and colorectal cancer in Missouri. *LGBT Health*. 2015;2(2):188-92.
2. Clavelle K, King D, Bazzi AR, Fein-Zachary V, Potter J. Breast cancer risk in sexual minority women during routine screening at an urban LGBT health center. *Womens Health Issues*. 2015;25(4):341-8.
3. Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. *Cancer*. 2005;104(8):1733-41.
4. Dibble SL, Roberts SA. Improving cancer screening among lesbians over 50: results of a pilot study. *Oncol Nurs Forum*. 2003;30(4):E71-9.
5. Schulz M, Cukr P, Ludwick R. Developing a community based screening program: commitment to the underserved. *J Am Acad Nurse Pract*. 1999;11(6):249-252.

Reason for exclusion: Intervention out of scope (n = 6)

6. Phillips N, Sharma A, Horne J. Male to female trans-gender menopause. *J Womens Health*. 2014;23(4):15-16.
7. Brown GR, Jones KT. Incidence of breast cancer in a cohort of 5,135 transgender veterans. *Breast Cancer Res Treat*. 2015;149(1):191-8.
8. Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. *J Sex Med*. 2013;10(12):3129-34.
9. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinol*. 2011;164(4):635-42.
10. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. *Clin Endocrinol (Oxf)*. 1997;47(3):337-42.
11. Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone

therapy in a large cohort of trans persons: a case-control study. *Eur J Endocrinol.* 2013;169(4):471-8.

Reason for exclusion: Outcomes of interest not reported (n = 2)

12. Bazzi AR, Whorms DS, King DS, Potter J. Adherence to mammography screening guidelines among transgender persons and sexual minority women. *Am J Public Health.* 2015;105(11):2356-57.
13. Scheim A, Bauer G. Breast and Cervical Cancer Screening among Trans Ontarians: A report prepared for the Screening Saves Lives Program of the Canadian Cancer Society [Internet]. Ontario, Canada: Trans PULSE Project; 2013 [cited 2017 Jun 20]. Available from: http://transpulseproject.ca/wp-content/uploads/2013/11/Trans-PULSE-Cancer-Screening-Report-for-Screening-Saves-Lives-V_Final.pdf.

Reason for exclusion: Study design out of scope (n = 18)

14. Katayama Y, Motoki T, Watanabe S, Miho S, Kimata Y, Matsuoka J, et al. A very rare case of breast cancer in a female-to-male transsexual. *Breast Cancer.* 2016;23(6):939-44.
15. Brown GR. Breast cancer in transgender veterans: a ten-case series. *LGBT Health.* 2015;2(1):77-80.
16. Walsh CM, Yang L, Park JM, Askeland RW, Fajardo LL. Angiolipoma of the breast in a transgender patient. *Breast J.* 2014;20(6):662-3.
17. Maglione KD, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, et al. Breast cancer in male-to-female transsexuals: use of breast imaging for detection. *AJR Am J Roentgenol.* 2014;203(6):W735-40.
18. Nikolic DV, Djordjevic ML, Granic M, Nikolic AT, Stanimirovic VV, Zdravkovic D, et al. Importance of revealing a rare case of breast cancer in a female to male transsexual after bilateral mastectomy. *World J Surg Oncol.* 2012;10:280.
19. Bowman E, Oprea G, Okoli J, Gundry K, Rizzo M, Gabram-Mendola S, et al. Pseudoangiomatous stromal hyperplasia (PASH) of the breast: a series of 24 patients. *Breast J.* 2012;18(3):242-7.
20. Alhabshi SMI, Ismail Z, Arasaratnam SA. Primary non-Hodgkin B cell lymphoma in a man. *Iran J Radiol.* 2011;8(1):39-41.
21. Dhand A, Dhaliwal G. Examining patient conceptions: a case of metastatic breast cancer in an African American male to female transgender patient. *J Gen Intern Med.* 2010;25(2):158-61.
22. Burcombe RJ, Makris A, Pittam M, Finer N. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. *Breast.* 2003;12(4):290-3.
23. Pattison ST, McLaren BR. Triple negative breast cancer in a male-to-female transsexual. *Intern Med J.* 2013;43(2):203-5.

24. Shao T, Grossbard ML, Klein P. Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management. *Clin Breast Cancer*. 2011; 11(6):417-9.
25. Gooren L, Bowers M, Lips P, Konings IR. Five new cases of breast cancer in transsexual persons. *Andrologia*. 2015;47(10):1202-5.
26. Teoh ZH, Archampong D, Gate T. Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?. *BMJ Case Rep*. 2015; doi: 10.1136/bcr-2015-209396.
27. Corman V, Potorac I, Manto F, Dassay S, Segers K, Thiry A, et al. Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation. *Endocr Relat Cancer*. 2016;23(5):391-7.
28. Edmiston EK, Donald CA, Sattler AR, Peebles JK, Ehrenfeld JM, and Eckstrand KL. Opportunities and gaps in primary care preventative health services for transgender patients: a systematic review. *Transgend Health*. 2016;1(1):216-30.
29. Grabellus F, Worm K, Willruth A, Schmitz KJ, Otterbach F, Baba HA, et al. ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. *Breast*. 2005;14(1):71-4.
30. Sattari M. Breast cancer in male-to-female transgender patients: a case for caution. *Clin Breast Cancer*. 2015;15(1):e67-9.
31. Tongson K, Konovalova V, Dhawan N, Sharma S, Bahl J, Masri M. Breast cancer suspicion in a transgender male-to-female patient on hormone replacement therapy presenting with right breast mass: breast cancer risk assessment and presentation of a rare lesion. *Case Rep Oncol Med*. 2017; doi: 10.1155/2017/5172072.

Reason for exclusion: Publication type out of scope (n = 17)

32. Irwig MS. Clinical dilemmas in the management of transgender men. *Curr Opin in Endocrinol Diabetes Obes*. 2017;24(3):233-9.
33. Gondusky CJ, Kim MJ, Kalantari BN, Khalkhali I, Dauphine CE. Examining the role of screening mammography in men at moderate risk for breast cancer: two illustrative cases. *Breast J*. 2015; 21(3):316-7.
34. Oriel KA. Clinical update: medical care of transsexual patients. *J Gay Lesbian Med Assoc*. 2000;4(4):185-94.
35. Dean L, Meyer IH, Robinson K, Sell RL, Sember R, Silenzio VMB, et al. Lesbian, gay, bisexual, and transgender health: findings and concerns. *J Gay Lesbian Med Assoc*. 2000;4(3):101-51.
36. Feldman JL, Goldberg J. Transgender primary medical care: suggested guidelines for clinicians in British Columbia [Internet]. Vancouver, BC: Vancouver Coastal Health, Transcend Transgender Support & Education Society, and the Canadian Rainbow Health Coalition; 2006 [cited 2017 Jun 20]. Available from:

http://lgbtqpn.ca/wp-content/uploads/woocomerce_uploads/2014/08/Guidelines-primarycare.pdf.

37. Canadian Cancer Society, Toronto Central Regional Cancer Program and Rainbow Health. Lesbian, gay, bisexual, transgender and queer (LGBTQ) populations and cancer screening [Internet]. Toronto, ON: Canadian Cancer Society; 2015 [cited 2017 Jun 20]. Available from: http://convio.cancer.ca/site/DocServer/CME_LGBTcancerScreening-Final.pdf.
38. Trans Care BC. Caring for trans and gender diverse clients in BC: a primary care toolkit [Internet]. British Columbia, Canada: Trans Care BC; 2017 [cited 2017 Jun 20]. Available from: <http://www.phsa.ca/transgender/Documents/Primary%20Care%20Toolkit.pdf>.
39. Center of Excellence for Transgender Health. Guidelines for the primary and gender-affirming care of transgender and gender non-binary people – 2nd edition [Internet]. San Francisco: University of California, San Francisco; 2016 [cited 2017 Jun 20]. Available from: <http://transhealth.ucsf.edu/protocols>.
40. Burkhalter J, Margolies L, Sigurdsson HO, Walland J, Radix A, Rice D, et al. The national LGBT cancer action plan: a white paper of the 2014 national summit on cancer in the LGBT communities. *LGBT Health*. 2016;3(1):19-31.
41. Lawrence A. Transgender health concerns. In: Meyer IH, Northridge ME, editors. *The health of sexual minorities: public health perspectives on lesbian, gay, bisexual and transgender populations*. First edition. United States: Springer US; 2007. p.473-505.
42. Phillips J, Fein-Zachary VJ, Mehta TS, Littlehale N, Venkataraman S, Slanetz PJ. Breast imaging in the transgender patient. *Am J Roentgenol*. 2014; 202(5):1149-56.
43. Spack NP. Management of transgenderism. *JAMA*. 2013;309(5):478-84.
44. Gooren LJ. Care of transsexual persons. *N Engl J Med*. 2011;364(13):1251-7.
45. Mueller A, Gooren LJ. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. *Eur J Endocrinol*. 2008; 159(3):197-202.
46. Maycock LB, Kennedy HP. Breast care in the transgender individual. *J Midwifery Womens Health*. 2014;59(1):74-81.
47. Braun H, Nash R, Tangpricha V, Brockman J, Ward K, Goodman M. Cancer in transgender people: evidence and methodological considerations. *Epidemiol Rev*. 2017;39(1):93-107.
48. Quinn GP, Sanchez JA, Sutton SK, Vadaparampil ST, Nguyen GT, Green BL, et al. Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. *CA Cancer J Clin*. 2015;65(5):384-400.

Review Three: Breast Screening for Trans Populations: A Systematic Review of Guidelines and Position Statements

Documents excluded at full-text screening (n = 15)

Reason for exclusion: Population out of scope (n = 2)

1. Adelson SL, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter on gay, lesbian, or bisexual sexual orientation, gender nonconformity, and gender discordance in children and adolescents. *J Am Acad Child Adolesc Psychiatry*. 2012;51(9):957-74.
2. Canadian Cancer Society. Breast cancer screening information for lesbian, gay, bisexual and queer women [Internet]. Canada: Canadian Cancer Society; 2017 [cited 2017 Feb 16]. Available from: http://convio.cancer.ca/site/PageServer?pagename=SSL_ON_HCP_HCPL_Breast#.WKYDGm8rKUK.

Reason for exclusion: Does not address key question (n = 9)

3. Canadian Association of Radiologists. Breast disease. In: 2012 CAR Diagnostic Imaging Referral Guidelines [Internet]. Canada: Canadian Association of Radiologists; 2012 [cited 2017 Feb 16]. Available from: <http://www.car.ca/uploads/standards%20guidelines/car-referralguidelines-m-en-20151022.pdf>.
4. Canadian Association of Radiologists. CAR practice guidelines and technical standards for breast imaging and intervention [Internet]. Canada: Canadian Association of Radiologists; 2016 [updated 2016 Sept 17; cited 2017 Feb 18]. Available from: http://www.car.ca/uploads/standards%20guidelines/car_breastimagingguidelines_2016_en.pdf.
5. Canadian Cancer Society. LGBTQ cancer screening (Get screened): working with LGBTQ communities to increase early detection and regular screening for colon, breast and cervical cancers [Internet]. Canada: Canadian Cancer Society; 2017 [cited 2017 Feb 16]. Available from: <http://www.cancer.ca/en/prevention-and-screening/early-detection-and-screening/screening/get-screened-on/?region=on>.
6. National Comprehensive Cancer Network. Breast cancer screening and diagnosis [Internet]. Washington, PA: National Comprehensive Cancer Network; 2015 [cited 17 February 2017]. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/PDF/breast-screening.pdf.
7. Ontario College of Family Physicians. Caring for transgender patients [Internet]. Toronto, ON: Ontario College of Family Physicians; 2016 [cited 2017 Feb 16]. Available from: <http://ocfp.on.ca/communications/caring-for-transgender-patients>.
8. Evans DT. Lesbian, gay, bisexual and transgender patients or clients - guidance for nursing staff on next-of-kin issues [Internet]. London, UK: Royal College of Nursing;

2012 [cited 2017 Feb 16]. Available from:
https://my.rcn.org.uk/_data/assets/pdf_file/0015/520512/002017.pdf.

9. World Professional Association for Transgender Health. Standards of care for the health of transsexual, transgender, and gender nonconforming people [Internet]. Version 7. Place published unknown: World Professional Association; 2011 [cited 2017 Feb 16]. Available from:
http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&pk_association_webpage=3926.
10. Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. *CMAJ*. 2011;183(17):1991-2001.
11. Medical Foundation for AIDS & Sexual Health. Recommended standards for sexual health services [Internet]. London, UK: Medical Foundation for AIDS & Sexual Health; 2005 [cited 2017 Feb 18]. Available from:
<http://www.medfash.org.uk/uploads/files/p17abl5efr149kgsu10811h21i3tt.pdf>.

Reason for exclusion: Publication type out of scope (n = 3)

12. Centre for Excellence in Cancer Prevention. Frequently asked questions about preventing breast cancer [Internet]. Vancouver, BC: Center of Excellence in Cancer Prevention; 2016 [cited 2017 Feb 18]. Available from:
https://cancerprevent.ca/sites/cancerprevent.ca/files/documents/BrCa_FAQs_2016_1013.pdf.
13. Rainbow Health Ontario. Evidence brief: LGBTQ cancer factsheet [Internet]. Toronto, ON: Rainbow Health Ontario; 2016 [cited 2017 Feb 18]. Available from:
https://www.rainbowhealthontario.ca/wp-content/uploads/woocommerce_uploads/2016/07/RHO_FactSheet_LGBTQCANCER_-07.31.16.pdf.
14. Ashbee O, Mira J. Trans people and cancer [Internet]. Vancouver, BC: Transcend Transgender Support & Education and Vancouver Coastal Health; 2006 [cited 2017 Feb 16]. Available from: http://www.rainbowhealthontario.ca/wp-content/uploads/woocommerce_uploads/2014/08/Cancer.pdf.

Reason for exclusion: Article could not be obtained (n = 1)

15. Makadon HJ, Mayer KH, Potter J and Goldhammer H. The Fenway guide to lesbian, gay, bisexual, and transgender health. Second edition. United States: American College of Physicians; 2015.